Menu
image description

Tag: MD

Less Risk and Greater Efficacy in Pediatric Lupus Nephritis Treatment

November 3, 2020 There is no doubt about it. The research into the mechanisms of pediatric lupus nephritis conducted by Elena Hsieh, MD, at the University of Colorado Anschutz Medical Campus, is driven by her genuine concern for the wellbeing of children—and a lifelong passion for science. With her new grant from the Lupus Research […] Read More

Overcoming the Uncertainties of Living with Chronic Diseases like Lupus

July 21, 2022 Interview with Michael D. Lockshin, MD, MACR Director Emeritus, Barbara Volcker Center for Women and Rheumatic Disease and Co-Director, Mary Kirkland Center for Lupus Research at Hospital for Special Surgery; Professor of Medicine and Obstetrics-Gynecology at Joan and Sanford Weill College of Medicine of Cornell University   Uncertainty and unpredictability are among […] Read More

Lupus Research Alliance Applauds U.S. FDA Approval of AstraZeneca’s anifrolumab-fnia (Saphnelo™) for Systemic Lupus Erythematosus (SLE)

  First in New Class of Drugs in More than a Decade for SLE Targeting Type 1 Interferons NEW YORK, NY. August 2, 2021. The Lupus Research Alliance (LRA) is particularly excited about the U.S. Food and Drug Administration (FDA) approval of anifrolumab-fnia (Saphnelo™), a first-in-class type I interferon receptor antagonist indicated for adults with […] Read More

LRA Applauds GSK on Positive Phase 3 Study of Benlysta® in Lupus Nephritis

September 16, 2020 NEW YORK, NY. The Lupus Research Alliance welcomes positive BLISS-LN Phase 3 data published in this week’s New England Journal of Medicine, demonstrating that GSK’s drug Benlysta® (belimumab) significantly improved kidney function in adults with lupus nephritis, the most common severe complication of lupus causing inflammation and serious damage to the kidney. The […] Read More

Watch Webcast Video: Redefining Lupus Trials Amid COVID-19 and Beyond

Videotape of 8.24.20 Learn from Lupus Zoom Webcast Ensuring the clinical trial process is accommodating for participants has always been the goal. However, COVID-19 has forced industry, research organizations, doctors, and patients to think twice about the process and its impact on high-risk populations including people with lupus who are immunocompromised. In light of COVID-19, […] Read More

NIH Leader and LRA Board Member Key Author on Promising COVID-19 Vaccine

August 13, 2020 The Lupus Research Alliance (LRA) is encouraged by a promising animal study in the New England Journal of Medicine co-authored by Robert Seder, MD, Chief of the Cellular Immunology Section in the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH) […] Read More